Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
|ClinicalTrials.gov Identifier: NCT02676843|
Recruitment Status : Enrolling by invitation
First Posted : February 8, 2016
Last Update Posted : October 27, 2016
|Condition or disease||Intervention/treatment||Phase|
|Frontotemporal Lobar Degeneration FTLD Frontotemporal Dementia FTD Tauopathies||Drug: 18F-AV-1451||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Subjects will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
- Evidence of Tau deposition on PET scan [ Time Frame: Through completion of PET scan, approximately 30 minutes ]Each subject's PET scan will be qualitatively examined for tau positivity.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02676843
|United States, New York|
|Morton A. Kreitchman PET Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Edward Huey, MD||Columbia University|